Alan Burnett



Prosiectau fel Prif Ymchwiliwr
null null 2 o 5 null null

AML 15 Trial Support Account - Cyllidwr:Wyeth Pharmaceuticals (01.07.2002 - 31.07.2010)
In vitro evaluation of novel agents in AML - Cyllidwr:Sunesis Pharmaceuticals Inc (13.12.2007 - 12.12.2008)
A protocol for patients aged under 60 - AML 15 - Cyllidwr:Teva UK Ltd (18.09.2006 - 31.12.2009)


Prosiectau fel Cyd-Ymchwiliwr
null null 2 o 2 null null

Cancer Genetics Biomedical Research Unit - Cyllidwr:Welsh Government (HCRW) (31.03.2011 - 31.05.2015)
Investigation of the role of RAL dysregulation in myeloid leukaemia - Cyllidwr:Leukaemia Research Fund (01.11.2008 - 31.10.2011)
CD200: A putative target of AML - Cyllidwr:Leukaemia Research Fund (01.12.2008 - 30.11.2011)
Role of OGG1 in the pathogenesis of acute myeloid leukaemia - Cyllidwr:Welsh Government (01.04.2009 - 30.09.2011)

Diweddarwyd y tro diwethaf ar 2020-23-02 am 05:07